logo

FDA Calendar

Share
PDUFA dates and FDA Panel Review dates are very important because they are make or break events for biostocks when the decisions are announced. Also, usually biostocks experience a run-up going into the scheduled decision/review dates. So having prior knowledge of the catalysts goes a long way toward maximizing profit or minimizing loss while trading volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes biotech and pharma sectors. Check out our premium biotech research product and our biotech home page.
Company Name
Ticker
Drug
Event
Date
Outcome
Details
Roche Holding AG
Tecentriq (sBLA)
FDA decision on Tecentriq in Combination with Abraxane for Initial Treatment of People with PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
03/12/2019
FDA grants accelerated approval to Tecentriq in combination with Abraxane on Mar 11
Regeneron Pharmaceuticals
Dupixent (sBLA)
FDA decision on expanded use of Dupixent as a treatment for adolescents with moderate-to-severe atopic dermatitis
03/11/2019
FDA approves Dupixent
Johnson & Johnson
Spravato (NDA)
FDA final decision on Spravato for adults living with treatment-resistant depression
03/04/2019
FDA approves SPRAVATO on Mar 5
Novo Nordisk A/S
N8-GP (BLA)
FDA decision on N8-GP for treatment of people with haemophilia A
02/27/2019
FDA approveD ESPEROCT on Feb 19, 2019
Karyopharm Therapeutics Inc.
Selinexor (NDA)
FDA panel to review Selinexor for the treatment of patients with refractory multiple myeloma who have received at least three prior therapies
02/26/2019
FDA panel voted 8 to 5 recommending that the FDA wait for Phase 3 study results of Selinexor
Bausch Health Companies Inc.
BHC, BHC.TO
Loteprednol etabonate ophthalmic gel (NDA)
FDA decision on Loteprednol etabonate ophthalmic gel for post-operative inflammation and pain following ocular surgery
02/25/2019
FDA approves LOTEMAX SM (loteprednol etabonate ophthalmic gel) for the treatment of postoperative inflammation and pain following ocular surgery
Incyte Corporation
Ruxolitinib (sNDA)
FDA decision on Ruxolitinib for the treatment of steroid-refractory acute GVHD
02/24/2019
FDA decision extended by 3 months to May 24, 2019.
Stemline Therapeutics Inc
ELZONRIS (BLA)
FDA decision on ELZONRIS for the treatment of blastic plasmacytoid dendritic cell neoplasm
02/21/2019
FDA approved ELZONRIS on Dec.21, 2018
Alexion Pharmaceuticals Inc.
ALXN1210 (BLA)
FDA decision on ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria
02/18/2019
FDA approved Ultomiris (also known as ALXN1210) on Dec.21
Merck & Co Inc.
KEYTRUDA (sBLA)
FDA decision on KEYTRUDA in the treatment of resected, high-risk stage III melanoma
02/16/2019
FDA Approves KEYTRUDA on Feb 19
Bausch Health Companies Inc.
BHC, BHC.TO
DUOBRII (Resubmitted NDA)
FDA decision on DUOBRII for the topical treatment of plaque psoriasis.
02/15/2019
MOTIF BIO PLC
Iclaprim (NDA)
FDA decision on Iclaprim for acute bacterial skin and skin structure infections
02/13/2019
FDA declines to approve Iclaprim for ABSSSI
Johnson & Johnson
Esketamine (NDA)
FDA panel to review Esketamine for the treatment of treatment-resistant depression.
02/12/2019
FDA panel backs Esketamine for the treatment of treatment-resistant depression.
Evolus Inc.
DWP-450(Resubmitted BLA)
FDA decision on DWP-450 for treatment of moderate to severe glabellar lines
02/02/2019
FDA approved Jeuveau (DWP-450) for treatment of moderate to severe glabellar lines on Feb.1, 2019
Alkermes plc
ALKS 5461 (NDA)
FDA’s final decision on ALKS 5461 for adjunctive treatment of major depressive disorder
01/31/2019
FDA rejected ALKS 5461 for adjunctive treatment of major depressive disorder on Feb.1, 2019


famousfive-041019.jpg The biotech sector got off to a good start in 2019, and the iShares Nasdaq Biotechnology ETF (IBB), a bellwether of investor sentiment, has so far gained 17 percent.
pharma-030718_09apr19.jpg Today's Daily Dose brings you news about the inter partes review decision on Concert Pharma's patents related to CTP-543; the proposed public offering of Daré Bioscience and Zosano Pharma; United Therapeutics' decision to discontinue the development of a PAH drug and FDA's refusal to review Zogenix' seizure drug candidate FINTEPLA.
pharma-030617_05apr19.jpg Today's Daily Dose brings you news about the upcoming key milestones of Stealth BioTherapeutics; the extended partnership between Natural Alternatives and The Juice Plus+ Company; Merrimack's discontinuation of phase I study of MM-310 for the treatment of solid tumors; and Sangamo's pricing of its public offering.
Read More
The conventional wisdom is that if the brain cells of humans and other mammals are deprived of oxygen for 4-5 min, they begin to die, and that the loss of brain functions after death is irreversible. But the findings of a study conducted by Yale University researchers challenge these long-held assumptions.
Canadian marijuana producer Aurora Cannabis Inc. (ACB, ACB.TO) has agreed to acquire the remaining 48 percent stake in Hempco Food and Fiber Inc. (HEMP.V) that it does not already own, in a deal that values Hempco at about C$63.4 million. Shares of Hempco gained more than 10 percent in Tuesday's trading. Aurora...
Canadian cannabis company Aphria Inc. (APHA) on Monday reported a net loss for the third quarter and also said it has entered into a series of transactions to accelerate the expiry date of the hostile takeover bid launched by Green Growth Brands Inc. The company's shares lost more than 14 percent in...
Read More